Clostridium difficile-associated diarrhea following the therapy with antibiotic and proton pump inhibitors in a 77-year-old man with several comorbidities: A case report.

Abstract

RATIONALE:

Clostridium difficile-associated diarrhea (CDAD) remains a persistent challenge, with substantially increased incidence and severity. The rising burden of CDAD requires urgent identification of preventable risk factors.

PATIENTS CONCERNS:

A 77-year-old man with the symptoms of abdominal pain and watery diarrhea was readmitted to the hospital, who received cephalosporins and proton pump inhibitors (PPIs) during the initial hospitalization for 12 days until discharge. Antibiotic-associated diarrhea was seriously suspected. And the stool sample was immediately sent for inspection for C difficile. He had a history of chronic bronchitis, coronary heart disease, and osteonecrosis.

DIAGNOSIS:

CDAD, renal insufficiency INTERVENTIONS:: Oral vancomycin was administered for 14 days.

OUTCOMES:

On the third day after readmission, the stool sample turned out to be positive for both C difficile toxin and its antigen. After 10-day treatment with vancomycin, diarrhea symptoms disappeared and his stools became normal.

LESSONS:

In elderly patients with multiple comorbidities, PPIs must be administered cautiously to minimize the risk for adverse effects including CDAD. It is important to identify the preventable risk factors of CDAD for clinicians and pharmacists. Oral vancomycin therapy seems to be effective in CDAD.

• Authors: Xiaoqun Lv, Jun Zhang, Miao Jiang, Yujuan Liu, Weifang Ren, Zhonghong Fang
• Journal: Medicine (Medicine (Baltimore)) Vol. 98 Issue 13 Pg. e15004 (Mar 2019) ISSN: 1536-5964 [Electronic] United States
• PMID: 30921218 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Proton Pump Inhibitors
• Vancomycin

Topics

• Aged
• Anti-Bacterial Agents (adverse effects, therapeutic use)
• Clostridioides difficile
• Comorbidity
• Diarrhea (chemically induced, drug therapy)
• Enterocolitis, Pseudomembranous (chemically induced, drug therapy)
• Humans
• Male
• Proton Pump Inhibitors (adverse effects)
• Vancomycin (therapeutic use)